Page 2 - Bryan Chow News Today

Immunotherapy, a biotherapy that boosts the ability of the immune system to recognize and attack mutant tumor cells, has transformed the treatment landscape for patients battling cancer, which emerges from the progressive accumulation of DNA mutations.

New research from Yale Cancer Center reveals for the first time ever a differential clinical response to pembrolizumab in Lynch-like (mutated) vs methylated microsatellite instability-high (MSI-H) uterine cancer patients, increasing our understanding about the proportion of patients that derive benefit from immune checkpoint blockade.

Immunotherapy, a biotherapy that boosts the ability of the immune system to recognize and attack mutant tumor cells, has transformed the treatment landscape for patients battling cancer, which emerges from the progressive accumulation of DNA mutations. However, many patients do not respond to immunotherapy.

Yale researchers have found that a mechanism for faulty DNA repair in tumors is a key factor in determining whether patients respond to immunotherapy.

Mastering automation to accelerate business transformation within healthcare organizations.

Overcoming objections to automation within your healthcare organization.

Will medical establishments face million-dollar penalties in October?

Scoop Community provides New Zealand Community news and views

Even though the United States spends twice as much on cancer care as other high-income countries, cancer mortality rates are only marginally better than average.

Study finds no relationship between cancer spending and the cancer death rate.